Prospective study of high dose MTX with R-CHOP therapy for primary central nervous system lymphoma.
Phase 2
- Conditions
- Primary CNS lymphoma (CD20+ diffuse large B-cell lymphoma)
- Registration Number
- JPRN-UMIN000001343
- Lead Sponsor
- Hematology and Immunology, Kanazawa Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1, extra-CNS lesion 2, severe infectious disease 3, pre-treatment history for lymphoma 4, HIV+, HTLV1+, HBs-Ag+ 5, physician's decision of inappropriateness
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival, CR rate
- Secondary Outcome Measures
Name Time Method Adverse events